Expected Impact of Biosimilars on the Pharmaceutical Companies

Stay connected! Follow us on X network (Twitter):

Share By

Expected Impact of Biosimilars on the Pharmaceutical Companies Publisher Pubmed

Golshani S^{1, 2} ; Faramarzi MA¹

Source: Iranian Journal of Medical Sciences Published:2021

[No abstract available]

Style	Citing Format
MLA	Golshani S, Faramarzi MA. "Expected Impact of Biosimilars on the Pharmaceutical Companies." Iranian Journal of Medical Sciences, vol. 46, no. 5, 2021, pp. 399-401.
APA	Golshani S, Faramarzi MA (2021). Expected Impact of Biosimilars on the Pharmaceutical Companies. Iranian Journal of Medical Sciences, 46(5), 399-401.
Chicago	Golshani S, Faramarzi MA. "Expected Impact of Biosimilars on the Pharmaceutical Companies." Iranian Journal of Medical Sciences 46, no. 5 (2021): 399-401.
Harvard	Golshani S, Faramarzi MA (2021) 'Expected Impact of Biosimilars on the Pharmaceutical Companies', Iranian Journal of Medical Sciences, 46(5), pp. 399-401.
Vancouver	Golshani S, Faramarzi MA. Expected Impact of Biosimilars on the Pharmaceutical Companies. Iranian Journal of Medical Sciences. 2021;46(5):399-401.
BibTex	@article{ author = {Golshani S and Faramarzi MA}, title = {Expected Impact of Biosimilars on the Pharmaceutical Companies}, journal = {Iranian Journal of Medical Sciences}, volume = {46}, number = {5}, pages = {399-401}, year = {2021} }
RIS	TY - JOUR AU - Golshani S AU - Faramarzi MA TI - Expected Impact of Biosimilars on the Pharmaceutical Companies JO - Iranian Journal of Medical Sciences VL - 46 IS - 5 SP - 399 EP - 401 PY - 2021 ER -